. 2023 Jun 7;28(12):1072–1078. doi: 10.1093/oncolo/oyad154

Table 3.

Associations between immune related adverse events and clinical outcomes in urothelial cancer patients using multivariable analysis.^a

Variable		OS		PFS		CB
Variable		HR (CI)	P-value	HR (CI)	P-value	OR (CI)	P-value
irAE (n = 25)		0.38 (0.18-0.79)	0.009 ^b	0.27 (0.14-0.53)	<0.001 ^b	4.2 (1.35-13.06)	0.013 ^b
irAE (n = 25)	Median months (CI)	NR (9.9, NR)		8.5 (3.3, NR)
No irAE (n = 45)		1		1		1^c
No irAE (n = 45)	Median months (CI)	7.1 (2.4, 11.7)		2.2 (1.7, 3.2)
Dermatologic irAE (n = 9)		0.23 (0.07-0.78)	0.019 ^b	0.18 (0.06-0.53)	0.002 ^b	7.68 (1.51-38.93)	0.014 ^b
Dermatologic irAE (n = 9)	Median months (CI)	NR (5.5, NR)		33.3 (2.8, NR)
No dermatologic irAE (n = 61)		1		1		1^c
No dermatologic irAE (n = 61)	Median months (CI)	9.2 (5.8, 12.4)		2.6 (2.2, 3.8)

Statistically significant P-values are bolded.

^aMultivariable analysis was built using the backward selection method at alpha level of 0.1.

^bStatistical significance at alpha < 0.05.

^cSix patients were removed from CB analysis due to missing chart information.

Abbreviations: CB, clinical benefit; HR, hazard ratio; irAE, immune related adverse events; OS, overall survival; PFS, progression-free survival; OR, odds ratio